Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure
Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure
复制标题
DOI：
10.1046/j.1365-2362.2003.01187.x
复制
发表时间：
2003-08-01
影响因子：
5.5
通讯作者：
Ghigliotti, G
中科院分区：
文献类型：
--
作者：
Altieri, P;Brunelli, C;Ghigliotti, G
背景心力衰竭的进展与心脏和远离心脏的区域的间质性改变有关。在心力衰竭患者的心室组织中发现金属蛋白酶2和9以及金属蛋白酶组织抑制剂1和2的表达增强。我们的目的是确定心力衰竭患者血浆中是否也存在金属蛋白酶-2、金属蛋白酶-9和金属蛋白酶组织抑制剂-1和金属蛋白酶组织抑制剂-2的活性增加。设计测定了51例心力衰竭患者静脉血中金属蛋白酶-2、金属蛋白酶-9和金属蛋白酶组织抑制剂-1和金属蛋白酶组织抑制剂-2的水平，并与52名对照受试者的水平进行比较。结果与对照组相比，心力衰竭患者的前金属蛋白酶-9（95.1+/-11.2和38.9 +/-4.5（星号））、活化的明胶酶活性（酶谱）和蛋白水平（平均值± SE，ng/mL-1）显著升高，而血浆中的明胶酶活性（95.1+/-11.2和38.9+/-4.5（星号））显著降低（P < 0.01）。金属蛋白酶-9（18.4 ± 2.5和10.9 ± 1.3（星星））和金属蛋白酶原-2（571.4 ± 26-1和456.8 ± 21.1（星星））（分别为：患者和对照受试者; P-星星
Background Progression of heart failure is associated with interstitial changes in the heart and in areas distant from the heart. Enhanced expression of metalloproteinases 2 and 9 and of metalloproteinases tissue inhibitors 1 and 2 have been found in ventricular tissue of patients with heart failure. Our aim was to determine whether increased activity of metalloproteinase-2, metalloproteinase-9 and of metalloproteinases tissue inhibitor-1 and metalloproteinases tissue inhibitor-2 were also present in plasma of patients with heart failure.Design Levels of metalloproteinase-2, metalloproteinase-9 and of metalloproteinase tissue inhibitor-1 and metalloproteinases tissue inhibitor-2 were measured in venous blood of 51 patients with heart failure, and were compared with levels of 52 control subjects. Samples collected from patients and control subjects were assayed for gelatinolytic activity (zymography) and for protein levels.Results Compared with the control subjects, the patients with heart failure had a significant increase in activity levels (mean+/-SE, ng mL(-1)) of prometalloproteinase-9 (95.1+/-11.2 and 38.9+/-4.5(star)), activ. metalloproteinase-9 (18.4+/-2.5 and 10.9+/-1.3(star)), and of prometalloproteinase-2 (571.4+/-26-1 and 456.8+/-21.1(star)) (respectively: patients and control subjects; P-star